Metabolic Diseases
![Image](https://www.envolbio.com/wp-content/uploads/2023/10/Envol_Icons-08.png)
Normal, obese and/or diabetic study subjects.
![Image](https://www.envolbio.com/wp-content/uploads/2023/10/Envol_Icons-03.png)
Colonies of dysmetabolic cynomolgus and marmosets.
![Image](https://www.envolbio.com/wp-content/uploads/2023/10/Envol_Icons-02.png)
Acute, short-infusion or repeated dosing designs.
![Image](https://www.envolbio.com/wp-content/uploads/2023/10/Envol_Icons-07.png)
Full clinical chemistry, clinical pathology and clinical toxicology support.
![Image](https://www.envolbio.com/wp-content/uploads/2023/10/Envol_Icons-11.png)
Tissue-specific safety biomarker levels by biosampling, biopsy or microdialysis.
![Image](https://www.envolbio.com/wp-content/uploads/2023/10/Envol_Icons-11.png)
Organ-specific or complete histology and pathology evaluation.
Comprehensive metabolic status testing
- Oral or IV glucose tolerance test (GTT)
- Meal tolerance test (MTT)
- Lipid tolerance test (LTT)
- Normal insulin suppression test (NIST)
- Graded glucose infusion test (GGT)
- Insulin tolerance test (ITT)
- Normo-insulinemic or hyper-insulinemic glucose clamps
Comprehensive dysmetabolic biomarkers assays
- Glucose, insulin and c-peptide (NHP validated assays)
- Lipid panels
- Endocrine hormone panels (NHP validated assays)